Department of Radiation Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Department of Gastrointestinal, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Biomed Res Int. 2020 Jan 22;2020:1487609. doi: 10.1155/2020/1487609. eCollection 2020.
Circular RNAs (circRNAs) have been shown to be involved in tumorigenesis. As a member of circRNAs, ciRS-7 is thought to be a negative prognostic indicator in multiple types of cancer. The present study aimed to comprehensively explore the value of ciRS-7 in tumor malignancy. . A systematic review of PubMed, Web of Science, and the Cochrane library was carried out to examine the related studies. The pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated from the available publications by STATA 12.0. Subgroup analysis, publication bias, sensitivity analysis, and meta-regression were conducted.
This meta-analysis included 1,714 patients from 13 cohorts. The results suggested that high ciRS-7 expression was significantly associated with overall survival (OS) (HR = 2.17, 95% CI = 1.50-3.15, < 0.001) in various cancers. Stratified analyses indicated that elevated levels of ciRS-7 appeared to be a powerful prognostic biomarker for patients with non-small-cell lung cancer (NSCLC) (HR: 2.50, 95% CI: 1.07-6.07, < 0.001) in various cancers. Stratified analyses indicated that elevated levels of ciRS-7 appeared to be a powerful prognostic biomarker for patients with non-small-cell lung cancer (NSCLC) (HR: 2.50, 95% CI: 1.07-6.07, < 0.001) in various cancers. Stratified analyses indicated that elevated levels of ciRS-7 appeared to be a powerful prognostic biomarker for patients with non-small-cell lung cancer (NSCLC) (HR: 2.50, 95% CI: 1.07-6.07, < 0.001) in various cancers. Stratified analyses indicated that elevated levels of ciRS-7 appeared to be a powerful prognostic biomarker for patients with non-small-cell lung cancer (NSCLC) (HR: 2.50, 95% CI: 1.07-6.07, < 0.001) in various cancers. Stratified analyses indicated that elevated levels of ciRS-7 appeared to be a powerful prognostic biomarker for patients with non-small-cell lung cancer (NSCLC) (HR: 2.50, 95% CI: 1.07-6.07.
High expression of ciRS-7 has a significant correlation with the high stage in various cancers, and ciRS-7 is intimately associated with an adverse OS in numerous cancers. Thus, ciRS-7 may act as a potential biomarker for the development of malignancies.
环状 RNA(circRNAs)已被证明参与肿瘤发生。作为 circRNAs 的一员,ciRS-7 被认为是多种癌症的预后不良指标。本研究旨在全面探讨 ciRS-7 在肿瘤恶性程度中的价值。 系统检索了 PubMed、Web of Science 和 Cochrane 图书馆,以查阅相关研究。采用 STATA 12.0 计算来自可用出版物的合并优势比(OR)和风险比(HR)及其 95%置信区间(95%CI)。进行了亚组分析、发表偏倚、敏感性分析和荟萃回归。 结果:该荟萃分析纳入了来自 13 个队列的 1714 名患者。结果表明,ciRS-7 高表达与各种癌症的总生存期(OS)(HR=2.17,95%CI=1.50-3.15,<0.001)显著相关。分层分析表明,ciRS-7 水平升高似乎是各种癌症非小细胞肺癌(NSCLC)患者的强大预后生物标志物(HR:2.50,95%CI:1.07-6.07,<0.001)。分层分析表明,ciRS-7 水平升高似乎是各种癌症非小细胞肺癌(NSCLC)患者的强大预后生物标志物(HR:2.50,95%CI:1.07-6.07,<0.001)。分层分析表明,ciRS-7 水平升高似乎是各种癌症非小细胞肺癌(NSCLC)患者的强大预后生物标志物(HR:2.50,95%CI:1.07-6.07,<0.001)。分层分析表明,ciRS-7 水平升高似乎是各种癌症非小细胞肺癌(NSCLC)患者的强大预后生物标志物(HR:2.50,95%CI:1.07-6.07,<0.001)。分层分析表明,ciRS-7 水平升高似乎是各种癌症非小细胞肺癌(NSCLC)患者的强大预后生物标志物(HR:2.50,95%CI:1.07-6.07,<0.001)。
ciRS-7 高表达与多种癌症的高分期显著相关,ciRS-7 与多种癌症的不良 OS 密切相关。因此,ciRS-7 可能是恶性肿瘤发生的潜在生物标志物。